---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-000398"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2026-01-20T23:59:59+00:00"
generated_at: "2026-05-16T09:35:40.309827+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "low"
source: SEC EDGAR
---

# Tivic Health releases corporate presentation highlighting late-stage pipeline in radiation damage and oncology

## Summary
- Company targeting multiple high-value inflection points expected within the next 18-24 months.
- Focus on competitively differentiated treatments for radiation damage, oncology, and immune system modification.
- Pipeline described as late-stage and highly de-risked; experienced management team in place.
- Corporate presentation furnished as Exhibit 99.1; no specific financial or clinical data disclosed.

## SEC filing metadata
- accession: 0001683168-26-000398
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2026-01-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000168316826000398/0001683168-26-000398-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000168316826000398/tivic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-000398
- JSON: https://secwatch.observer/filing/0001683168-26-000398.json
- Plain text: https://secwatch.observer/filing/0001683168-26-000398.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.